Navigation Links
Otix Global Receives Nasdaq Bid Price Notice Deficiency
Date:10/12/2009

SALT LAKE CITY, Oct. 12 /PRNewswire-FirstCall/ -- Otix Global, Inc. (Nasdaq: OTIX) today announced it has received a notice from The Nasdaq Stock Market that it is not in compliance with Nasdaq Listing Rule 5450(a)(1) because the closing bid price for its common stock has been below $1.00 per share for 30 consecutive business days. In accordance with the Nasdaq Listing Rules, Otix has 180 calendar days, or until April 5, 2010, to regain compliance with this rule. Should Otix's common stock close at $1.00 per share or more for at least 10 consecutive business days prior to April 5, 2010, compliance will have been achieved and the matter will be closed. This notification has no effect on the listing of Otix common stock at this time.

At its May 2009 annual shareholder meeting, Otix Global, Inc.'s shareholders approved a one-for-five reverse stock split, which has yet to be implemented. The company may implement this reverse stock split should it determine that such action is necessary.

ABOUT OTIX GLOBAL

Otix Global, Inc. is a global provider of superior hearing solutions. The company is passionate about quality, technology, and improving lives through enhanced hearing. The Otix Global family is dedicated to the growth and success of their hearing-healthcare partners. Otix Global is listed on the NASDAQ Global Market System (OTIX) and can be found online at www.otixglobal.com.

This press release may contain "forward-looking statements" as defined under securities laws. Actual results may differ materially and adversely from those described herein depending on a number of factors including, but not limited to, the following risks: we face aggressive competition in our business; acquisitions could be difficult to integrate and disrupt our current business and therefore may harm our operating results; we may not launch more product lines this year; our products may not help people hear better or more naturally; we may poorly operate newly acquired businesses; we may lose a large customer or suffer a reduction in orders from a large customer; we must have innovative, technologically superior products to compete effectively; our products, due to their complexity, may contain errors or defects that are only discovered after sales by our customers, thus harming our reputation and business; we may have issues with intellectual property; and we have important international operations, which expose us to a variety of risks including government reimbursement, that could impact sales and operating results. For additional information regarding the risks inherent in our business, please see "Factors That May Affect Future Performance" included in our Annual Report on Form 10-K for the year ended December 31, 2008, and Forms 10-Q for the quarters ended March 31, 2009 and June 30, 2009, as filed with the Securities and Exchange Commission.

We undertake no obligation to revise our forward-looking statements to reflect events or circumstances after the date hereof as a result of new information, future events or otherwise.

SOURCE Otix Global, Inc.


'/>"/>
SOURCE Otix Global, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Reportlinker Adds Global Medical Devices Industry Outlook to 2010: Marketing And Sales Strategies And The Impact of Recession And Recovery
2. Applied Seals North America Extends Global Network With Addition of Distributor in Europe
3. PEAK Surgical and Medtronic Announce Global Distribution Agreement for the Ear, Nose, and Throat Market
4. Signostics Introduces the Worlds Smallest Ultrasound Product for Global Demands of Affordable Healthcare
5. Health Robotics CytoCare(TM) Global Expansion Continues With Grifols International in Latin America
6. Galil Medical Announces Establishment of Global Headquarters in Minneapolis, MN
7. Pres. Clinton Announces Commitment From Inter-American Development Bank, Global Network for Neglected Tropical Diseases, and Pan American Health Organization to Mobilize $30 Million to Fight NTDs in the Americas at CGI Conference
8. New Large-Scale, Global Study Provides Additional Information About an Intensified Dose-Regimen of PLAVIX(R) in Acute Coronary Syndrome Patients Undergoing Angioplasty
9. European Division of Global Top 20 Pharmaceutical Company Awards Phase III Trial to DATATRAK
10. MacroGenics and Lilly Achieve Targeted Patient Enrollment in PROTEGE, a Global Phase 2/3 Clinical Trial of Teplizumab in Type 1 Diabetes
11. Lilly Advances Second Alzheimers Disease Treatment Candidate Into Late-Stage Testing by Launching Two Global Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/7/2017)... Diplomat Pharmacy, Inc. (NYSE: DPLO ) ... president, effective Aug. 7, 2017. ... other interests and will serve as president emeritus during a ... us in multiple leadership roles since he joined Diplomat with ... has provided decisive, strategic leadership which continues to benefit our ...
(Date:8/3/2017)... Aug. 3, 2017  Opioid addiction and other drugs ... healthcare costs and threatening outcomes, were problems taken on ... IVD industry that support them, met this week. This ... said that drugs of abuse, procalcitonin and acute kidney ... the organization,s 69th meeting in San Diego, ...
(Date:8/1/2017)...   CerSci Therapeutics , a non-opioid drug development ... has received notice from the National Institute on Drug ... that it has been awarded a Direct-to-Phase II Small ... 2017 with an additional $1,000,000 to follow in 2018. ... of their lead non-opioid drug candidate CT-044 to the ...
Breaking Medicine Technology:
(Date:8/16/2017)... ... August 16, 2017 , ... An August 3rd article on Reuters covers ... of a report in JAMA (the Journal of the American Medical Association). The study found ... to achieve BMIs under 30, when compared to patients with lower BMIs. At present, weight ...
(Date:8/16/2017)... GA (PRWEB) , ... August 16, 2017 , ... ... new Inc. 5000. The company ranked #4429 on the newly released, 36th annual ... list represents a unique look at the most successful companies within the American economy’s ...
(Date:8/16/2017)... Brentwood, TN (PRWEB) , ... August 16, 2017 ... ... market-leading dermatology practice partnerships through affiliations and de novo development, today announced ... practice. , Cumberland Skin Surgery and Dermatology, with offices in both Hermitage ...
(Date:8/16/2017)... ... 16, 2017 , ... Paul Vitenas, MD, FACS , is honored to ... annual list identifies the nation’s top physicians, in a variety of specialties. This marks ... top of Castle Connolly’s coveted ranking. , Castle Connolly is the nation’s trusted provider ...
(Date:8/16/2017)... ... August 16, 2017 , ... SGNA Standards of Infection Control ... cycle, both between patient procedures and before storage, is a requisite practice crucial ... to the prevention of disease transmission and nosocomial infection as cleaning and HLD.” ...
Breaking Medicine News(10 mins):